New hope for myeloma patients: drug combo shows promise without transplant

This study tests a combination of drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) as a first treatment for multiple myeloma patients who are not eligible for a stem cell transplant. After initial treatment, patients receive maintenance therapy with daratumumab, bortezomib, and dexamethasone until the disease progresses, and then they may be re-treated with daratumumab at first relapse. The goal is to see how well this approach controls the disease and reduces signs of cancer.